TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo February 8, 2023 Wei Zhang President CASI Pharmaceuticals Holdings, Inc. 1701-1702, China Central Office Tower 1 No. 81 Jianguo Road Chaoyang District Beijing, 100025 People s Republic of China Re: CASI Pharmaceuticals Holdings, Inc. Registration Statement on Form F-4 Filed on January 31, 2023 File No. 333-269479 Dear Wei Zhang: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter X. Huang, Esq.